Richard Hopkins is a founder of Phylogica and had been the chief executive since July 2013; he announced his resignation in July 2016. He then became chief executive of PharmAust Pharmaceutical for a year before becoming chief executive and managing director of Zelira Therapeutics in July 2018. He left Zelira in May 2021 following a strategic consolidation by the company to have its leadership team based in the US.
His most recent research was focused on engineering peptide leads for drug development. Dr Hopkins has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications.